

Marietta Kirchner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7321362/publications.pdf>

Version: 2024-02-01

38
papers

1,142
citations

567144

15
h-index

414303

32
g-index

38
all docs

38
docs citations

38
times ranked

1727
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 74, 1191-1198.	2.9	330
2	The Value of PSA Density in Combination with PI-RADS ² for the Accuracy of Prostate Cancer Prediction. <i>Journal of Urology</i> , 2017, 198, 575-582.	0.2	179
3	Cardiovascular Phenotypes in Children with CKD: The 4C Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 19-28.	2.2	138
4	Prevalence of Hypertension in Children with Early-Stage ADPKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 874-883.	2.2	65
5	Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children. <i>JAMA Pediatrics</i> , 2017, 171, e172914.	3.3	46
6	Low levels of urinary epidermal growth factor predict chronic kidney disease progression in children. <i>Kidney International</i> , 2019, 96, 214-221.	2.6	43
7	Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease. <i>Pediatric Nephrology</i> , 2019, 34, 2571-2582.	0.9	27
8	White Matter Microstructure in Youths With Conduct Disorder: Effects of Sex and Variation in Callous Traits. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2019, 58, 1184-1196.	0.3	23
9	“What would you like to achieve?” Goal-Setting in Patients with Dementia in Geriatric Rehabilitation. <i>BMC Geriatrics</i> , 2019, 19, 280.	1.1	22
10	The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma. <i>Radiotherapy and Oncology</i> , 2021, 159, 8-16.	0.3	21
11	Determinants of Statural Growth in European Children With Chronic Kidney Disease: Findings From the Cardiovascular Comorbidity in Children With Chronic Kidney Disease (4C) Study. <i>Frontiers in Pediatrics</i> , 2019, 7, 278.	0.9	19
12	Relational Aggression in Adolescents with Conduct Disorder: Sex Differences and Behavioral Correlates. <i>Journal of Abnormal Child Psychology</i> , 2019, 47, 1625-1637.	3.5	19
13	Discontinuation of RAAS Inhibition in Children with Advanced CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 625-632.	2.2	19
14	Serum indoxyl sulfate concentrations associate with progression of chronic kidney disease in children. <i>PLoS ONE</i> , 2020, 15, e0240446.	1.1	19
15	Sample size planning for phase II trials based on success probabilities for phase III. <i>Pharmaceutical Statistics</i> , 2015, 14, 515-524.	0.7	18
16	Cognitive Change in Rehabilitation Patients with Dementia: Prevalence and Association with Rehabilitation Success. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1171-1182.	1.2	18
17	Utility-based optimization of phase II/III programs. <i>Statistics in Medicine</i> , 2016, 35, 305-316.	0.8	15
18	Rotational thrombelastometry (ROTEM) improves hemostasis assessment compared to conventional coagulation test in ACLF and Non-ACLF patients. <i>BMC Gastroenterology</i> , 2020, 20, 271.	0.8	15

#	ARTICLE	IF	CITATIONS
19	Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Cancers, 2021, 13, 1223.	1.7	15
20	Arterial tissue transcriptional profiles associate with tissue remodeling and cardiovascular phenotype in children with end-stage kidney disease. Scientific Reports, 2019, 9, 10316.	1.6	12
21	Gene Polymorphisms of NOD2, IL23R, PTPN2 and ATG16L1 in Patients with Crohn's Disease: On the Way to Personalized Medicine?. Genes, 2021, 12, 866.	1.0	12
22	Robotic-Assisted Versus Conventional Open Partial Nephrectomy (Robocop): A Propensity Score-Matched Analysis of 249 Patients. Urologia Internationalis, 2021, 105, 490-498.	0.6	10
23	Plasma Lipidome, PNPLA3 polymorphism and hepatic steatosis in hereditary hemochromatosis. BMC Gastroenterology, 2020, 20, 230.	0.8	7
24	CDH12 as a Candidate Gene for Kidney Injury in Posterior Urethral Valve Cases: A Genome-wide Association Study Among Patients with Obstructive Uropathies. European Urology Open Science, 2021, 28, 26-35.	0.2	7
25	Implementation of a novel efficacy score to compare sealing and cutting devices in a porcine model. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 1002-1011.	1.3	6
26	Sex-specific associations of basal steroid hormones and neuropeptides with Conduct Disorder and neuroendocrine mediation of environmental risk. European Neuropsychopharmacology, 2021, 49, 40-53.	0.3	6
27	An adaptive design for early clinical development including interim decision for single-arm trial with external controls or randomized trial. Pharmaceutical Statistics, 2022, 21, 625-640.	0.7	5
28	Optimal designs for phase II/III drug development programs including methods for discounting of phase II results. BMC Medical Research Methodology, 2020, 20, 253.	1.4	4
29	Influence of Cognitive Impairment on Rehabilitation Received and Its Mediating Effect on Functional Recovery. Journal of Alzheimer's Disease, 2021, 84, 745-756.	1.2	4
30	Simulation-based adjustment after exploratory biomarker subgroup selection in phase II. Statistics in Medicine, 2017, 36, 2378-2390.	0.8	3
31	Optimal planning of phase II/III programs for clinical trials with multiple endpoints. Pharmaceutical Statistics, 2018, 17, 437-457.	0.7	3
32	Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performed. Biometrical Journal, 2019, 61, 357-378.	0.6	3
33	Assessment of rotational thrombelastometry (ROTEM) parameters in hepatocellular carcinoma. Thrombosis Research, 2020, 195, 55-57.	0.8	3
34	Probability of success for phase III after exploratory biomarker analysis in phase II. Pharmaceutical Statistics, 2017, 16, 178-191.	0.7	2
35	Optimal Designs for Multi-Arm Phase II/III Drug Development Programs. Statistics in Biopharmaceutical Research, 2021, 13, 71-81.	0.6	2
36	Adjustment for exploratory cutoff selection in randomized clinical trials with survival endpoint. Biometrical Journal, 2020, 62, 627-642.	0.6	1

#	ARTICLE	IF	CITATIONS
37	ROBOCOP II (ROBOtic assisted versus conventional open partial nephrectomy) randomised, controlled feasibility trial: clinical trial protocol. <i>BMJ Open</i> , 2021, 11, e052087.	0.8	1
38	Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II / III data on response and overall survival. <i>Pharmaceutical Statistics</i> , 2020, 19, 861-881.	0.7	0